Established in 2018, InxMed strives to be a China-based global new drug development engine dedicated to the development of innovative drugs with high probability of success and meaningful value for patients globally by execution of our “Best-in-Disease Combination” strategy and leveraging China clinical resources.
In InxMed, we think differently, because we know the deep understanding of disease biology and value-driven study design are how we differentiate from others.
In InxMed, we value the highest efficiency in execution and expeditious generation of “PoC” data, because we know “Vision without execution is hallucination”.
In InxMed, we believe combination therapy is the future for oncology, and triple or multiple drug combinations are emerging with great potential.
In InxMed, we strive to build up a pipeline consisting of “First-in-Class” and “Best-in-Disease Combination” assets, driven by intrinsic potential of synergy.
Company Details
- Employees
- 17
- Founded
- -
- Address
- 515 Huanke Road, Greenland M-Town Tower 1, Pudong New District, Shanghai,shanghai 201202,china
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.inxmed.com
- HQ
- Shanghai, Shanghai
Inxmed 应世生物 Questions
Inxmed 应世生物's website is http://www.inxmed.com
Inxmed 应世生物's LinkedIn profile is https://cn.linkedin.com/company/inxmed-%E5%BA%94%E4%B8%96%E7%94%9F%E7%89%A9
Inxmed 应世生物 has
17 employees.
View email and phone details for 17
employees at Inxmed 应世生物.
Inxmed 应世生物's industry is
Biotechnology Research
Inxmed 应世生物's top competitors are
Curon Biopharmaceutical,
Visen Pharmaceuticals,
Biontech Se,
Asieris Pharmaceuticals,
Cytovation,
Innolake Biopharm,
Aivita Biomedical, Inc.,
Eluminex Biosciences Limited,
Recbio,
Quantx Biosciences.
Inxmed 应世生物's categories are Biotechnology Research
Inxmed 应世生物's founding year is 2018
